Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090129 · ClinicalTrials.gov registry record · Phase 3
Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis
A Phase 3 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 3
- Development phase
- 854
- Enrollment target
NCT00090129 is a Phase 3 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 854 participants.
The verdict
NCT00090129, a Phase 3 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 854 participants
- Enrollment target
Study Summary
The is a double-blind, placebo-controlled, randomized, and multicenter study consisting of a first treatment (FT) period followed by either an observation (OB) period and a re-treatment (RT) period or an open-label (OL) treatment period, depending on FT period response, and a 4-week safety follow-up (FU) period. The purpose of this study is to evaluate the safety and efficacy of onercept, to be administered as 150 milligram (mg) three times a week, compared to matching placebo, for the induction of remission in subjects with moderate to severe plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG Onercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 854 participants |
| Start Date | 2004-09 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090129
The ClinicalTrials.gov registry entry for NCT00090129 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 854 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00090129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090129 about?
NCT00090129 is a clinical study titled "Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis". The is a double-blind, placebo-controlled, randomized, and multicenter study consisting of a first treatment (FT) period followed by either an observation (OB) period and a re-treatment (RT) period or an open-label (OL) treatment period, depending on FT period response, and a 4-week safety follow-up...
What is the current status of trial NCT00090129?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 854 participants. The study started on 2004-09. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00090129?
The interventions under investigation include: Placebo (DRUG), Onercept (DRUG).
Who is sponsoring clinical trial NCT00090129?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.